June 02, 2011

Press Release No. 1

Clarification by KDL Biotech Limited.

Significant price and volume movement has been observed in KDL Biotech Limited.

The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company.

KDL Biotech Limited has vide its letter inter-alia stated, "There is no information or announcement that could have a bearing on the operation or the performance of the company which has not been intimated to the exchange in terms of the listing agreement."

Press Release No. 1

NSE completes its 2816^th Normal Settlement

The Exchange has successfully completed its 2816^th Normal Settlement (Rolling T+2 following SEBI directive) since inception i.e., Settlement Number N – 2011102 on Jun 02, 2011. The settlement statistics are as follows:

Particulars	Value
	N-2011102
Total traded quantity (lakhs)	7010.61
Total traded value (Rs. In Crores)	15313.38
Total value of the settlement (Securities) (Rs. In Crores)	5223.60
Total value of the settlement (Funds) (Rs. In Crores)	2297.29
Shortages for the settlement	0.10%
% of Delivery ( No. of shares deliverable / No. of shares traded )	33.23%

Retail Debt Market has completed its 2089^th settlements, details of which are as follows:

Settlement No.	Traded Value	Settlement Value
		Securities	Funds
D- 2011102	NIL	NIL	NIL